MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST New York, USA, and Melbourne, Australia: August 24, 2026 : Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and...
Mesoblast 2026 Full Year Financial Results Webcast
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Mesoblast
- Major Milestone Treatment Completed in P3 Trial for CLBP
- Becoming a substantial holder
- Ceasing to be a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Later from Mesoblast
- Notification regarding unquoted securities - MSB
- Appendix 3Y - Philip Krause
- Preliminary Final Report including Appendix 4E
- Annual Financial Results Presentation
- MSB Annual Financial Results and Operational Update
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast
